Yeah $35 million doesn't go far in the pharma research industry. If Galliprant was selling as well as it was being touted to they should have money rolling in. But it's not, sitting stagnant on shelves at the price point they have it at right now.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.